| An inflammatory cytokine signature predicts COVID-19 severity and survival DM Del Valle, S Kim-Schulze, HH Huang, ND Beckmann, S Nirenberg, ... Nature medicine 26 (10), 1636-1643, 2020 | 2278 | 2020 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 771 | 2021 |
| A conserved dendritic-cell regulatory program limits antitumour immunity B Maier, AM Leader, ST Chen, N Tung, C Chang, J LeBerichel, ... Nature 580 (7802), 257-262, 2020 | 574 | 2020 |
| Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination L Hammerich, TU Marron, R Upadhyay, J Svensson-Arvelund, ... Nature medicine 25 (5), 814-824, 2019 | 340 | 2019 |
| Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells M Casanova-Acebes, E Dalla, AM Leader, J LeBerichel, J Nikolic, ... Nature 595 (7868), 578-584, 2021 | 327 | 2021 |
| Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification AM Leader, JA Grout, BB Maier, BY Nabet, MD Park, A Tabachnikova, ... Cancer cell 39 (12), 1594-1609. e12, 2021 | 175 | 2021 |
| Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 138 | 2022 |
| Toll-like receptor 7 and 9 defects in common variable immunodeficiency EY Joyce, AK Knight, L Radigan, TU Marron, L Zhang, S Sanchez-Ramón, ... Journal of allergy and clinical immunology 124 (2), 349-356. e3, 2009 | 135 | 2009 |
| High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency AK Knight, L Radigan, T Marron, A Langs, L Zhang, ... Clinical immunology 124 (2), 182-189, 2007 | 104 | 2007 |
| Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial TU Marron, MI Fiel, P Hamon, N Fiaschi, E Kim, SC Ward, Z Zhao, J Kim, ... The Lancet Gastroenterology & Hepatology 7 (3), 219-229, 2022 | 101 | 2022 |
| Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors JA Grout, P Sirven, AM Leader, S Maskey, E Hector, I Puisieux, F Steffan, ... Cancer Discovery 12 (11), 2606-2625, 2022 | 88 | 2022 |
| Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 85 | 2021 |
| Considerations for treatment duration in responders to immune checkpoint inhibitors TU Marron, AE Ryan, SM Reddy, S Kaczanowska, RH Younis, D Thakkar, ... Journal for immunotherapy of cancer 9 (3), 2021 | 83 | 2021 |
| Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity S Chakraborty, JC Gonzalez, BL Sievers, V Mallajosyula, S Chakraborty, ... Science Translational Medicine 14 (635), eabm7853, 2022 | 80 | 2022 |
| Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma A Magen, P Hamon, N Fiaschi, BY Soong, MD Park, R Mattiuz, E Humblin, ... Nature medicine 29 (6), 1389-1399, 2023 | 62 | 2023 |
| Toll-like receptor 4–, 7–, and 8–activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines TU Marron, M Martinez-Gallo, EY Joyce, C Cunningham-Rundles Journal of allergy and clinical immunology 129 (1), 184-190. e4, 2012 | 62 | 2012 |
| Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 57 | 2020 |
| Perspectives on the neoadjuvant use of immunotherapy in hepatocellular carcinoma DJ Pinato, P Fessas, G Sapisochin, TU Marron Hepatology 74 (1), 483-490, 2021 | 55 | 2021 |
| Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma A Pavlick, AB Blazquez, M Meseck, M Lattanzi, PA Ott, TU Marron, ... Cancer immunology research 8 (1), 70-80, 2020 | 54 | 2020 |
| Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 54 | 2020 |
